Genome editing human primary T cells with microfluidic vortex shedding & CRISPR Cas9
J. A. Jarrell, B. J. Sytsma, L. H. Wilson, F. L. Pan, K. H. W. J. Lau, G. T. S. Kirby, A. A. Lievano, R. S. Pawell
This study evaluates microfluidic vortex shedding (VS) and electric field-enhanced VS (eVS) for delivering CRISPR-Cas9 RNP to primary human T cells, showing improved editing efficiency and cell viability compared to electroporation.
bioRxiv · Feb 26, 2020 · PreprintImmunology